Firma faCellitate, Autor bei Presse-Blog

faCellitate Announces Results of a Study on 3D Cell Culture:

7. März 20248. März 2024 Firma faCellitateBiotechnikbiofloat, cells, coated plates, coatings, drug screening, facellitate, high-throughput screening, lauschke, low adhesion plates, research, spheroid, tissue, ula

Publication in Biotechnology Journal A broadly designed comparative study conducted by researchers from Karolinska Institute in Stockholm has shown that BIOFLOAT™ 3D Cell Culture Plates have performance characteristics superior over all other 3D Cell Culture Plates investigated. Mannheim (Germany) and Mehr

faCellitate gibt die Ergebnisse einer Studie zur 3D-Zellkultur bekannt:

26. Februar 2024 Firma faCellitateBiotechnikbiofloat, cells, coated plates, coatings, drug screening, facellitate, high-throughput screening, low adhesion plates, microplates, platten, Sphäroid, Studie, tierversuche, tissue, well

Veröffentlichung im Biotechnology Journal Eine breit angelegte Vergleichsstudie, die von Forschenden des Karolinska Instituts in Stockholm durchgeführt wurde, hat gezeigt, dass BIOFLOAT™ 3D-Zellkulturplatten Leistungsmerkmale besitzen, die den anderen untersuchten 3D-Zellkulturplatten überlegen sind. Mannheim (Deutschland) und Stockholm (Schweden), 26. Februar Mehr

faCellitate 2023: Cutting-edge Flat-Bottom microplates with Ultra-Low Adhesion Surface

6. Dezember 20236. Dezember 2023 Firma faCellitateBiotechnikbiofloat, cell, cells, coated microplate, coatings, drug screening, facellitate, flat bottom, high-throughput screening, imaging, low adhesion plate, microplate, organoids, ula

faCellitate expands its product range with the launch of three new BIOFLOAT™ -coated flat-bottom microplates; a 96-well format, soon to be followed by 24- and 6-well plates. This innovative series is purposefully crafted as an addition to the BIOFLOAT 96-well Mehr

faCellitate appoints Christoph Petry, Ph.D. to become Managing Director and CEO

30. November 20226. Februar 2023 Firma faCellitateAllgemein3D Cell Culture, biofloat, breast cancer, endopredict, facellitate, high-throughput screening, labs, m2p, myriad, organoid, siemens, sividon, spheroid, therapy

faCellitate GmbH has appointed Dr. Christoph Petry, as Managing Director and CEO. Dr. Petry spun-out Sividon Diagnostics from Siemens Healthcare in 2010. Serving as Sividon’s CEO he oversaw the development of EndoPredict, a new standard to target breast cancer therapy Mehr

faCellitate Starts Marketing New 384-well Spheroid Microplate

11. Oktober 20226. Februar 2023 Firma faCellitateAllgemein384 ula, assay, cell, cells, centrifugation free, coatings, drug screening, facellitate, high-throughput screening, hts, low adhesion plate, microplate, organoid, spheroid

faCellitate expands its BIOFLOAT™ coated microplate portfolio by a 384 well format specifically designed for spheroid culture The exceptional performance of the BIOFLOAT™ coating combined with the high density 384-format makes the new product solution particularly valuable for high-throughput spheroid Mehr

faCellitate, ein BASF-Spin-off, schließt eine 3,7 Mio. € Seed-Runde unter Führung von SARSTEDT und dem HTGF ab

7. September 20226. Februar 2023 Firma faCellitateAllgemein3D Zellkultur, basf, Chemovator, facellitate, htgf, Life Science, organoid, Pharmaforschung, sarstedt, Sphäroid, ULA Mikrotestplatte, Zelltherapie

Erfolgreiches Closing der Seedrunde über 3,7 Millionen Euro unter Beteiligung von SARSTEDT, High-Tech Gründerfonds (HTGF), R3 Consulting, ARVE Capital, ROI Verwaltungsgesellschaft und Chemovator. faCellitate hat eine intelligente und extrem niedrig anhaftende Plattform für Polymeroberflächenbeschichtungen entwickelt. Das erste auf dem Markt Mehr

faCellitate, a BASF spin-off, closes a €3.7m seed round led by SARSTEDT and HTGF

7. September 20226. Februar 2023 Firma faCellitateAllgemein3D Cell Culture, basf, cell therapy, Chemovator, facellitate, htgf, Life Science, organoid, pharma, sarstedt, spheroid, ULA microplate

Closing of seed round completed raising €3.7 million from SARSTEDT, High-Tech Gründerfonds (HTGF), R3 Consulting, ARVE Capital, ROI Verwaltungsgesellschaft and Chemovator. faCellitate has developed an intelligent and ultra-low attachment polymer surface coating platform. The first launched product thereof is targeting Mehr

Autor: Firma faCellitate